![Mark Baldry](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Baldry
No open positions remaining
Net worth: 109 202 $ as of 31/05/2026
Profile
Mark Baldry formerly worked at Biogen, Inc., as Vice President-New Product Commercialization, Amicus Therapeutics, Inc., as SVP-Global Marketing & Commercial Operations, Shire Plc, as Head-Marketing & Market Access EMEA, Wave Life Sciences Ltd., as Chief Commercial Officer, Freeline Therapeutics Holdings Ltd., as Chief Commercial Officer from 2020 to 2022, Wave Life Sciences USA, Inc., as Chief Commercial Officer from 2019 to 2020, and X4 Pharmaceuticals, Inc., as Chief Commercial Officer from 2022 to 2025.
Mr. Baldry received his undergraduate degree from York University and Masters Business Admin degree from Concordia University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 16/05/2025 | 25,337 ( 0.03% ) | 109 202 $ | 31/05/2026 |
Former positions of Mark Baldry
| Companies | Position | End |
|---|---|---|
| X4 PHARMACEUTICALS, INC. | Corporate Officer/Principal | 15/09/2025 |
| FREELINE THERAPEUTICS HOLDINGS PLC | Corporate Officer/Principal | 01/10/2022 |
Wave Life Sciences USA, Inc.
 Wave Life Sciences USA, Inc. Electric UtilitiesUtilities Provides nucleic acid therapeutics | Corporate Officer/Principal | 01/02/2020 |
| AMICUS THERAPEUTICS, INC. | Sales & Marketing | 01/07/2019 |
| BIOGEN INC. | Public Communications Contact | 01/05/2015 |
Training of Mark Baldry
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
17
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Amicus Therapeutics, Inc.
 Amicus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures novel medicines for rare diseases | Health Technology |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
Wave Life Sciences Ltd.
 Wave Life Sciences Ltd. BiotechnologyHealth Technology Operates as a biotechnology company that develops RNA oligonucleotides medicines | Health Technology |
York University
 York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Concordia University
 Concordia University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wave Life Sciences USA, Inc.
Wave Life Sciences USA, Inc. Electric UtilitiesUtilities Provides nucleic acid therapeutics | Utilities |
X4 Pharmaceuticals, Inc.
 X4 Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Develops and manufactures next-generation gene therapies | Health Technology |
- Stock Market
- Insiders
- Mark Baldry
Choose MarketScreener 
